Literature DB >> 3790074

The effect of desferrioxamine on transferrin receptors, the cell cycle and growth rates of human leukaemic cells.

A Bomford, J Isaac, S Roberts, A Edwards, S Young, R Williams.   

Abstract

The effect of the iron chelator, desferrioxamine, on transferrin binding, growth rates and the cell cycle was investigated in the human leukaemic cell line, K562. At all concentrations of the chelator (2-50 microM) binding of 125I-transferrin was increased by 24 h and reached a maximum at 72-96 h. Maximum binding (6-8-fold increased) occurred in cells treated with 20 microM-desferrioxamine, in contrast with control cells which, at 96 h, showed a 50% decrease over initial binding. Scatchard analysis at 4 degrees C showed that this increased binding was due to an increase in the number of receptors, as the Kd was similar in induced (1.8 nM) and control (1.5 nM) cells. After 96 h cells, cultured with 20 and 50 microM-desferrioxamine accumulated 59Fe from bovine transferrin at over twice the rate found with control cells, reflecting the increase in transferrin receptors. Although iron uptake was unimpaired by the chelator there was a dose-dependent inhibition of cell growth, with control cells completing three divisions in 96 h and those in 10 microM-desferrioxamine only two divisions. At the highest concentration (50 microM), cell division was abrogated although cell viability was maintained (85%). In contrast, DNA synthesis was not markedly affected, except at 50 microM-desferrioxamine when incorporation of [3H]thymidine was 52% of that in control cells. Flow cytometry revealed that there was a progressive accumulation of the cells in the active phases of their cycle (S, G2 + M). Desferrioxamine may increase transferrin receptors in two ways: by chelating a regulatory pool of iron within the cell, and by arresting cells in S phase when receptors are maximally expressed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3790074      PMCID: PMC1146812          DOI: 10.1042/bj2360243

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  38 in total

1.  Loss of epidermal growth factor requirement and malignant transformation.

Authors:  P V Cherington; B L Smith; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

2.  Iron salts and transferrin are specifically required for cell division of cultured 3T6 cells.

Authors:  P S Rudland; H Durbin; D Clingan; L J de Asua
Journal:  Biochem Biophys Res Commun       Date:  1977-04-11       Impact factor: 3.575

3.  Transferrin receptors on human B and T lymphoblastoid cell lines.

Authors:  J W Larrick; P Cresswell
Journal:  Biochim Biophys Acta       Date:  1979-04-03

4.  Growth and maintenance of HeLa cells in serum-free medium supplemented with hormones.

Authors:  S E Hutchings; G H Sato
Journal:  Proc Natl Acad Sci U S A       Date:  1978-02       Impact factor: 11.205

Review 5.  Reduction of ribonucleotides.

Authors:  L Thelander; P Reichard
Journal:  Annu Rev Biochem       Date:  1979       Impact factor: 23.643

6.  Release of iron from the two iron-binding sites of transferrin by cultured human cells: modulation by methylamine.

Authors:  A Bomford; S P Young; R Williams
Journal:  Biochemistry       Date:  1985-07-02       Impact factor: 3.162

7.  Cell-cycle analysis in 20 minutes.

Authors:  H A Crissman; R A Tobey
Journal:  Science       Date:  1974-06-21       Impact factor: 47.728

8.  Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells.

Authors:  A V Hoffbrand; K Ganeshaguru; J W Hooton; M H Tattersall
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

9.  Chelate mediated transfer of iron from transferrin to desferrioxamine.

Authors:  S Pollack; P Aisen; F D Lasky; G Vanderhoff
Journal:  Br J Haematol       Date:  1976-10       Impact factor: 6.998

10.  Iron: its intracellular localization and possible role in cell division.

Authors:  E Robbins; T Pederson
Journal:  Proc Natl Acad Sci U S A       Date:  1970-08       Impact factor: 11.205

View more
  8 in total

1.  Desferrithiocin is a more potent antineoplastic agent than desferrioxamine.

Authors:  Anthony Kicic; Anita C G Chua; Erica Baker
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Divergent effects of alpha 1-antitrypsin on the regulation of iron metabolism in human erythroleukaemic (K562) and myelomonocytic (THP-1) cells.

Authors:  G Weiss; I Graziadel; M Urbanek; K Grünewald; W Vogel
Journal:  Biochem J       Date:  1996-11-01       Impact factor: 3.857

3.  Species specificity of transferrin binding, endocytosis and iron internalization by cultured chick myogenic cells.

Authors:  L M Sorokin; E H Morgan
Journal:  J Comp Physiol B       Date:  1988       Impact factor: 2.200

4.  Chelation of transferrin iron by desferrioxamine in K562 cells. The partition of iron between ferrioxamine and ferritin.

Authors:  S Roberts; A Bomford
Journal:  Biochem J       Date:  1988-09-15       Impact factor: 3.857

5.  Assessing the transport of receptor-mediated drug-delivery devices across cellular monolayers.

Authors:  Erik Brewer; Anthony M Lowman
Journal:  J Biomater Sci Polym Ed       Date:  2013-12-24       Impact factor: 3.517

6.  Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity.

Authors:  E E Voest; J P Neijt; J E Keunen; A W Dekker; B S van Asbeck; J W Nortier; F E Ros; J J Marx
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Delivery of iron to human cells by bovine transferrin. Implications for the growth of human cells in vitro.

Authors:  S P Young; C Garner
Journal:  Biochem J       Date:  1990-01-15       Impact factor: 3.857

8.  The hepatic acute-phase proteins alpha 1-antitrypsin and alpha 2-macroglobulin inhibit binding of transferrin to its receptor.

Authors:  I Graziadei; R Kaserbacher; H Braunsteiner; W Vogel
Journal:  Biochem J       Date:  1993-02-15       Impact factor: 3.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.